Phenotypes associated with this allele

• Allele Symbol: Tg(TcrLCMV)327Sdz
• Allele Name: transgene insertion 327, Birgit Ledermann
• Allele ID: MGI:2665105
• Summary: 21 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Brca1^tm2Mak/Brca1^tm2Mak Tg(Lck-cre)548Jxm/? Tg(TcrLCMV)327Sdz/?	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:3834733
cn2	Prkcq^tm1Litt/Prkcq^tm1Litt Tg(TcrLCMV)327Sdz/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4843384
cx3	Casp3^tm1Mak/Casp3^tm1Mak Tg(TcrLCMV)327Sdz/0	B6.Cg-Casp3^tm1Mak Tg(TcrLCMV)327Sdz	MGI:3623578
cx4	Zap70^tm2.1Mmal/Zap70^tm2.1Mmal Tg(TcrLCMV)327Sdz/0	involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2	MGI:3790318
cx5	Zap70^tm1.1Mmal/Zap70^tm1.1Mmal Tg(TcrLCMV)327Sdz/0	involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2	MGI:3790319
cx6	Map2k6^tm1Ina/Map2k6^tm1Ina Tg(TcrLCMV)327Sdz/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:3692612
cx7	Cd28^tm1Mak/Cd28^tm1Mak Tg(TcrLCMV)327Sdz/0	involves: 129S2/SvPas * C57BL/6 * DBA/2	MGI:4843385
cx8	Rag1^tm1Mom/Rag1^tm1Mom Tg(LPV-TAg1135)11Tvd/0 Tg(TcrLCMV)327Sdz/0	involves: 129S7/SvEvBrd * C57BL/6 * DBA/2	MGI:2665134
cx9	Rag1^tm1Mom/Rag1^+ Tg(LPV-TAg1135)11Tvd/0 Tg(TcrLCMV)327Sdz/0	involves: 129S7/SvEvBrd * C57BL/6 * DBA/2	MGI:2665135
cx10	Erap1^tm1Luc/Erap1^tm1Luc Rag2^tm1Fwa/Rag2^tm1Fwa Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz	involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * C57BL/10SgSnAi * DBA/2	MGI:3714621
cx11	Elk4^tm1Rtr/Elk4^tm1Rtr Tg(TcrLCMV)327Sdz/?	involves: 129/Sv * C57BL/6 * DBA/2	MGI:3851780
cx12	Sit1^tm1Lsmn/Sit1^tm1Lsmn Tg(TcrLCMV)327Sdz/0	involves: C57BL/6	MGI:3589738
cx13	Serpinb9^tm1Arp/Serpinb9^tm1Arp Tg(TcrLCMV)327Sdz/0	involves: C57BL/6	MGI:3687316
cx14	Tg(Ins2-GP)#Psoh/0 Tg(TcrLCMV)327Sdz/0	involves: C57BL/6 * DBA/2	MGI:5568711
cx15	Tg(Ins1-Cd80)378Psoh/0 Tg(Ins2-GP)#Psoh/0 Tg(TcrLCMV)327Sdz/0	involves: C57BL/6 * DBA/2 * FVB/N	MGI:5569019
cx16	Tg(Ins1-Cd80)378Psoh/0 Tg(TcrLCMV)327Sdz/0	involves: C57BL/6 * DBA/2 * FVB/N	MGI:5569022
cx17	Tg(CD2-Zbtb7b)C8Rbo/? Tg(TcrLCMV)327Sdz/?	involves: C57BL/6 * DBA/2J	MGI:3817863
cx18	Prkdc^scid/Prkdc^scid Tg(TcrLCMV)327Sdz/?	NOD.Cg-Emv30^b Prkdc^scid Tg(TcrLCMV)327Sdz/DvsJ	MGI:3810167
tg19	Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz	NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs	MGI:3810256
tg20	Tg(TcrLCMV)327Sdz/0	involves: C57BL/6 * DBA/2	MGI:2665110
tg21	Tg(TcrLCMV)327Sdz/?	involves: C57BL/6 * DBA/2J	MGI:3817864

Genotype
MGI:3834733

cn1

• Allelic Composition: Brca1^tm2Mak/Brca1^tm2Mak; Tg(Lck-cre)548Jxm/?; Tg(TcrLCMV)327Sdz/?
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

decreased T cell proliferation ( J:63282 )

abnormal T cell number ( J:63282 )

decreased thymocyte number ( J:63282 )

increased double-negative T cell number ( J:63282 )

decreased double-positive T cell number ( J:63282 )

hematopoietic system

decreased T cell proliferation ( J:63282 )

abnormal T cell number ( J:63282 )

decreased thymocyte number ( J:63282 )

increased double-negative T cell number ( J:63282 )

decreased double-positive T cell number ( J:63282 )

endocrine/exocrine glands

decreased thymocyte number ( J:63282 )

cellular

decreased T cell proliferation ( J:63282 )

Genotype
MGI:4843384

cn2

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

immune system

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 partially restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

decreased cytotoxic T cell cytolysis ( J:123989 )

• after 3 days, cytotoxic T lymphocyte (CTL) activation in mice treated with gp33 peptide is decreased compared to in Tg(TcrLCMV)327Sdz mice

• splenocytes exposed to gp33 exhibit impaired CTL activation compared with similarly treated cells from Tg(TcrLCMV)327Sdz mice

• however, CTL activation in mice treated with gp33 peptide is normal at day 1 and treatment with IL2 restores CTL in splenocytes

abnormal T cell anergy ( J:123989 )

• cytotoxic T lymphocyte anergy is induced in mice treated with gp33 peptide unlike in similarly treated Tg(TcrLCMV)327Sdz mice

hematopoietic system

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 partially restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

decreased cytotoxic T cell cytolysis ( J:123989 )

• after 3 days, cytotoxic T lymphocyte (CTL) activation in mice treated with gp33 peptide is decreased compared to in Tg(TcrLCMV)327Sdz mice

• splenocytes exposed to gp33 exhibit impaired CTL activation compared with similarly treated cells from Tg(TcrLCMV)327Sdz mice

• however, CTL activation in mice treated with gp33 peptide is normal at day 1 and treatment with IL2 restores CTL in splenocytes

cellular

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 partially restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

Genotype
MGI:3623578

cx3

• Allelic Composition: Casp3^tm1Mak/Casp3^tm1Mak; Tg(TcrLCMV)327Sdz/0
• Genetic Background: B6.Cg-Casp3^tm1Mak Tg(TcrLCMV)327Sdz

homeostasis/metabolism

decreased physiological sensitivity to xenobiotic ( J:97650 )

• after injection with streptozocin for 5 consecutive days, blood glucose in caspase-3-homozygous transgenic mice remains normoglycemic for the duration of the study

cellular

decreased cell proliferation ( J:97650 )

• adoptive transfer of labeled Tg(TcrLCMV)327Sdz-transgene positive T cells, examination of pancreatic draining lymph nodes showed that only 45% of the transferred T cells had undergone proliferation compared to 62% in caspase-3-heterozygous transgenic recipients

immune system

abnormal CD8-positive, alpha beta T cell morphology ( J:97650 )

• in CD8+ T cells isolated from pancreatic draining or non-draining lymph nodes of streptozocin-treated mice, 32% of the CD8+ cells are CD69hi positive and 9% respectively, compared to corresponding values of 3% and 5% respectively in caspase-3-heterozygous transgenic mice

hematopoietic system

abnormal CD8-positive, alpha beta T cell morphology ( J:97650 )

• in CD8+ T cells isolated from pancreatic draining or non-draining lymph nodes of streptozocin-treated mice, 32% of the CD8+ cells are CD69hi positive and 9% respectively, compared to corresponding values of 3% and 5% respectively in caspase-3-heterozygous transgenic mice

Genotype
MGI:3790318

cx4

• Allelic Composition: Zap70^tm2.1Mmal/Zap70^tm2.1Mmal; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2

immune system

immune system phenotype ( J:71099 )

N • generation of CD8+/V alpha2^high thymocytes and lymph node T cells is normal

N • double negative and double positive cells from thymi of female mutants and wild-type mice have similar levels of CD5 expression

abnormal T cell morphology ( J:71099 )

• single positive thymocytes have lower CD5 surface expression than thymocytes from wild-type Tg(TcrLCMV)327Sdz or Tg(TcraH-Y,TcrbH-Y)71Vbo mice, or Zap70^tm1.1Mmal/ Tg(TcrLCMV)327Sdz or Zap70^tm1.1Mmal/ Tg(TcraH-Y,TcrbH-Y)71Vbo double mutants

hematopoietic system

abnormal T cell morphology ( J:71099 )

• single positive thymocytes have lower CD5 surface expression than thymocytes from wild-type Tg(TcrLCMV)327Sdz or Tg(TcraH-Y,TcrbH-Y)71Vbo mice, or Zap70^tm1.1Mmal/ Tg(TcrLCMV)327Sdz or Zap70^tm1.1Mmal/ Tg(TcraH-Y,TcrbH-Y)71Vbo double mutants

Genotype
MGI:3790319

cx5

• Allelic Composition: Zap70^tm1.1Mmal/Zap70^tm1.1Mmal; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * DBA/2

immune system

immune system phenotype ( J:71099 )

N • generation of CD8+/V alpha2^high thymocytes and lymph node T cells is normal

N • double negative and double positive cells from thymi of female mutants and wild-type mice have similar levels of CD5 expression

abnormal T cell proliferation ( J:71099 )

• when challenged with subnanomolar concentrations of p33 peptide in vitro, T cells proliferate more than wild-type Tg(TcrLCMV)327Sdz T cells

abnormal cytokine secretion ( J:71099 )

• T cells produce 2-3-fold more IL-2 in response to graded p33 concentrations in vitro compared to stimulated wild-type Tg(TcrLCMV)327Sdz or Zap70^tm2.1Mmal/ Tg(TcrLCMV)327Sdz T cells

• this is not observed at a single-cell level of cytokine production, indicating that increased IL-2 is result of greater T cell numbers

hematopoietic system

abnormal T cell proliferation ( J:71099 )

• when challenged with subnanomolar concentrations of p33 peptide in vitro, T cells proliferate more than wild-type Tg(TcrLCMV)327Sdz T cells

cellular

abnormal T cell proliferation ( J:71099 )

• when challenged with subnanomolar concentrations of p33 peptide in vitro, T cells proliferate more than wild-type Tg(TcrLCMV)327Sdz T cells

Genotype
MGI:3692612

cx6

• Allelic Composition: Map2k6^tm1Ina/Map2k6^tm1Ina; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

cellular

decreased apoptosis ( J:100093 )

• upon antigenic stimulation by injection of LCMV, caspase activation and DNA fragmentation in the TCRalphabeta^int thymocyte population is reduced compared to Map2k6-sufficient transgenic mice, while levels in the TCRalphabeta^hi population are comparable

• upon antigenic stimulation by injection of LCMV, deletion of TCR CD4^hiCD8^hi cells is less efficient than in Map2k6-sufficient transgenic mice

Genotype
MGI:4843385

cx7

• Allelic Composition: Cd28^tm1Mak/Cd28^tm1Mak; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: 129S2/SvPas * C57BL/6 * DBA/2

immune system

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

decreased cytotoxic T cell cytolysis ( J:123989 )

• after 3 days, cytotoxic T lymphocyte (CTL) activation in mice treated with gp33 peptide is decreased compared to in Tg(TcrLCMV)327Sdz mice

• splenocytes exposed to gp33 exhibit impaired CTL activation compared with similarly treated cells from Tg(TcrLCMV)327Sdz mice

• however, CTL activation in mice treated with gp33 peptide is normal at day 1 and treatment with IL2 restores CTL in splenocytes

abnormal T cell anergy ( J:123989 )

• cytotoxic T lymphocyte anergy in mice treated with gp33 peptide is induced unlike in similarly treated Tg(TcrLCMV)327Sdz mice

hematopoietic system

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

decreased cytotoxic T cell cytolysis ( J:123989 )

• after 3 days, cytotoxic T lymphocyte (CTL) activation in mice treated with gp33 peptide is decreased compared to in Tg(TcrLCMV)327Sdz mice

• splenocytes exposed to gp33 exhibit impaired CTL activation compared with similarly treated cells from Tg(TcrLCMV)327Sdz mice

• however, CTL activation in mice treated with gp33 peptide is normal at day 1 and treatment with IL2 restores CTL in splenocytes

cellular

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

Genotype
MGI:2665134

cx8

• Allelic Composition: Rag1^tm1Mom/Rag1^tm1Mom; Tg(LPV-TAg1135)11Tvd/0; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * DBA/2

mortality/aging

premature death ( J:47667 )

• survival time at which half of the mutants are sacrificed or die due to illness is 101 days

neoplasm

increased T cell derived lymphoma incidence ( J:47667 )

• 100% of mutants develop thymic lymphoma within the same accelerated time frame as mutants heterozygous for Rag1 and hemizygous for the two transgenes

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:47667 )

• 100% of mutants develop thymic lymphoma within the same accelerated time frame as mutants heterozygous for Rag1 and hemizygous for the two transgenes

hematopoietic system

increased T cell derived lymphoma incidence ( J:47667 )

• 100% of mutants develop thymic lymphoma within the same accelerated time frame as mutants heterozygous for Rag1 and hemizygous for the two transgenes

immune system

increased T cell derived lymphoma incidence ( J:47667 )

• 100% of mutants develop thymic lymphoma within the same accelerated time frame as mutants heterozygous for Rag1 and hemizygous for the two transgenes

Genotype
MGI:2665135

cx9

• Allelic Composition: Rag1^tm1Mom/Rag1⁺; Tg(LPV-TAg1135)11Tvd/0; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: 129S7/SvEvBrd * C57BL/6 * DBA/2

mortality/aging

premature death ( J:47667 )

• survival time at which half of the mutants are sacrificed or die due to illness is 110 days

neoplasm

increased T cell derived lymphoma incidence ( J:47667 )

• 100% incidence of thymoma

• tumorigenesis is accelerated compared to mice hemizygous for Tg(LPV-TAg1135)11Tvd and heterozygous for Rag1

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:47667 )

• 100% incidence of thymoma

• tumorigenesis is accelerated compared to mice hemizygous for Tg(LPV-TAg1135)11Tvd and heterozygous for Rag1

hematopoietic system

increased T cell derived lymphoma incidence ( J:47667 )

• 100% incidence of thymoma

• tumorigenesis is accelerated compared to mice hemizygous for Tg(LPV-TAg1135)11Tvd and heterozygous for Rag1

immune system

increased T cell derived lymphoma incidence ( J:47667 )

• 100% incidence of thymoma

• tumorigenesis is accelerated compared to mice hemizygous for Tg(LPV-TAg1135)11Tvd and heterozygous for Rag1

Genotype
MGI:3714621

cx10

• Allelic Composition: Erap1^tm1Luc/Erap1^tm1Luc; Rag2^tm1Fwa/Rag2^tm1Fwa; Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz
• Genetic Background: involves: 129S/SvEv * 129S6/SvEvTac * C57BL/6 * C57BL/10SgSnAi * DBA/2

immune system

immune system phenotype ( J:122479 )

N • CD8+ T cells show no differences in prevalence, numbers, or TCR expression levels relative to Arts1-sufficient Tg(TcrLCMV)327Sdz mice (on Rag2-null background)

Genotype
MGI:3851780

cx11

• Allelic Composition: Elk4^tm1Rtr/Elk4^tm1Rtr; Tg(TcrLCMV)327Sdz/?
• Genetic Background: involves: 129/Sv * C57BL/6 * DBA/2

hematopoietic system

abnormal positive T cell selection ( J:88515 )

• CD8 thymocyte positive selection is impaired: the proportion of CD8⁺ single positive thymocytes is reduced by about 75% and gating on TCR^hi cells show almost 90% reduction

decreased CD8-positive, alpha-beta T cell number ( J:88515 )

• the proportion of CD8⁺ single positive thymocytes is reduced by about 75% and gating on TCR^hi cells show almost 90% reduction

immune system

abnormal positive T cell selection ( J:88515 )

• CD8 thymocyte positive selection is impaired: the proportion of CD8⁺ single positive thymocytes is reduced by about 75% and gating on TCR^hi cells show almost 90% reduction

decreased CD8-positive, alpha-beta T cell number ( J:88515 )

• the proportion of CD8⁺ single positive thymocytes is reduced by about 75% and gating on TCR^hi cells show almost 90% reduction

Genotype
MGI:3589738

cx12

• Allelic Composition: Sit1^tm1Lsmn/Sit1^tm1Lsmn; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: C57BL/6

immune system

thymus hypoplasia ( J:100408 )

• dramatic reduction of thymic cellularity

abnormal T cell selection ( J:100408 )

• altered thymic selection process

abnormal positive T cell selection ( J:100408 )

• enhanced positive selection of T cells and partial conversion of positive selection to negative selection

hematopoietic system

thymus hypoplasia ( J:100408 )

• dramatic reduction of thymic cellularity

abnormal T cell selection ( J:100408 )

• altered thymic selection process

abnormal positive T cell selection ( J:100408 )

• enhanced positive selection of T cells and partial conversion of positive selection to negative selection

endocrine/exocrine glands

thymus hypoplasia ( J:100408 )

• dramatic reduction of thymic cellularity

Genotype
MGI:3687316

cx13

• Allelic Composition: Serpinb9^tm1Arp/Serpinb9^tm1Arp; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: C57BL/6

immune system

abnormal response to transplant ( J:113349 )

• when naive CD8 T cells transferred into B6 Ptprca recipients that were then infected with LCMV, numbers of viral-specific CTLs are reduced 7-fold compared to recipients receiving wild-type transgenic T cells

Genotype
MGI:5568711

cx14

• Allelic Composition: Tg(Ins2-GP)#Psoh/0; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: C57BL/6 * DBA/2

hematopoietic system

abnormal B cell selection ( J:81285 )

• skewing of thymocytes to the single CD8+ mature phenotype, indicating that thymocytes are positively selected

• however, double transgenic mice are able to respond by proliferation to LCMV antigens at the same magnitude as single Tg(TcrLCMV)327Sdz mice and cytotoxic T lymphocytes are able to respond to LCMV infection as in controls

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:209714 )

N • mice do not develop diabetes and exhibit normal islet architecture with no evidence of insulitis

hyperglycemia ( J:81285 )

• mice immunized with lymphocytic choriomeningitis virus (LCMV) develop hyperglycemia 3 to 4 days after infection

• a variant LCM virus, 8.7, does not induce diabetes in mice

increased urine glucose level ( J:81285 )

• mice immunized with LCMV develop glucosuria 3 to 4 days after infection

immune system

abnormal B cell selection ( J:81285 )

• skewing of thymocytes to the single CD8+ mature phenotype, indicating that thymocytes are positively selected

• however, double transgenic mice are able to respond by proliferation to LCMV antigens at the same magnitude as single Tg(TcrLCMV)327Sdz mice and cytotoxic T lymphocytes are able to respond to LCMV infection as in controls

renal/urinary system

increased urine glucose level ( J:81285 )

• mice immunized with LCMV develop glucosuria 3 to 4 days after infection

Genotype
MGI:5569019

cx15

• Allelic Composition: Tg(Ins1-Cd80)378Psoh/0; Tg(Ins2-GP)#Psoh/0; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: C57BL/6 * DBA/2 * FVB/N

mortality/aging

premature death ( J:209714 )

• hyperglycemia is followed by ketosis, wasting, and death

endocrine/exocrine glands

absent pancreatic beta cells ( J:209714 )

• complete beta-cell destruction

insulitis ( J:209714 )

• ongoing insulitis is seen at 10 weeks of age, with a diminished, but still present, mass of beta cells

• 4 week old mice show a mixture of a few cD8+ and CD4+ T lymphocytes and an increase in the number of macrophages surrounding pancreatic islets, while 9 week old mice show severe insulitis and periinsulitis with CD8+ and CD4+ T lymphocytes, macrophages and B lymphocytes infiltrating the islets

periinsulitis ( J:209714 )

• 9 week old mice show severe periinsulitis

growth/size/body

cachexia ( J:209714 )

• hyperglycemia is wasting

homeostasis/metabolism

hyperglycemia ( J:209714 )

• mice spontaneously become diabetic with a median age of hyperglycemia onset of 9-10 weeks of age

ketosis ( J:209714 )

• hyperglycemia is followed by ketosis

immune system

insulitis ( J:209714 )

• ongoing insulitis is seen at 10 weeks of age, with a diminished, but still present, mass of beta cells

• 4 week old mice show a mixture of a few cD8+ and CD4+ T lymphocytes and an increase in the number of macrophages surrounding pancreatic islets, while 9 week old mice show severe insulitis and periinsulitis with CD8+ and CD4+ T lymphocytes, macrophages and B lymphocytes infiltrating the islets

periinsulitis ( J:209714 )

• 9 week old mice show severe periinsulitis

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
type 1 diabetes mellitus		DOID:9744	OMIM:222100	J:209714

Genotype
MGI:5569022

cx16

• Allelic Composition: Tg(Ins1-Cd80)378Psoh/0; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: C57BL/6 * DBA/2 * FVB/N

homeostasis/metabolism

homeostasis/metabolism phenotype ( J:209714 )

N • mice do not develop spontaneous diabetes or diabetes when infected with a recombinant vaccinia virus expressing GP

Genotype
MGI:3817863

cx17

• Allelic Composition: Tg(CD2-Zbtb7b)C8Rbo/?; Tg(TcrLCMV)327Sdz/?
• Genetic Background: involves: C57BL/6 * DBA/2J

immune system

abnormal T cell differentiation ( J:97610 )

• mice have substantial numbers of transgenic CD4⁺ T cells while having a complete absence of transgenic CD8⁺ T cells, which is a reversal of the T cell populations that normally develop in mice carrying just the Tg(TcrLCMV)327Sdz allele

• the CD4 T cells bear high levels of the transgenic TCR, express CD154 upon activation, and have other hallmarks (lack perforin and IFN-gamma expression) of truly belonging to the CD4 lineage and not the CD8 lineage

hematopoietic system

abnormal T cell differentiation ( J:97610 )

• mice have substantial numbers of transgenic CD4⁺ T cells while having a complete absence of transgenic CD8⁺ T cells, which is a reversal of the T cell populations that normally develop in mice carrying just the Tg(TcrLCMV)327Sdz allele

• the CD4 T cells bear high levels of the transgenic TCR, express CD154 upon activation, and have other hallmarks (lack perforin and IFN-gamma expression) of truly belonging to the CD4 lineage and not the CD8 lineage

Genotype
MGI:3810167

cx18

• Allelic Composition: Prkdc^scid/Prkdc^scid; Tg(TcrLCMV)327Sdz/?
• Genetic Background: NOD.Cg-Emv30^b Prkdc^scid Tg(TcrLCMV)327Sdz/DvsJ

immune system

immune system phenotype ( J:71050 )

N • the presence of the T cell receptor transgene does not increase susceptibility to type 1 diabetes, even in the presence of this transgene NOD mice homozygous for the scid mutation do not develop type 1 diabetes

Genotype
MGI:3810256

tg19

• Allelic Composition: Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz
• Genetic Background: NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs

immune system

autoimmune response ( J:71050 )

• the rate and frequency of type 1 diabetes development in transgenic NOD females is the same as that in NOD females lacking the transgene

Genotype
MGI:2665110

tg20

• Allelic Composition: Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: C57BL/6 * DBA/2

immune system

decreased T cell proliferation ( J:77696 )

• response of uninfected transgenic Mls^a spleen cells to LCMV is reduced ~3-fold

thymus hypoplasia ( J:77696 )

• numbers of double-positive thymocytes and CD8+ thymocytes are drastically reduced in transgenic mice

decreased double-positive T cell number ( J:77696 )

• numbers of CD4+CD8+ thymocytes are drastically reduced in LCMV-tolerant (carrier) transgenic mice

decreased CD8-positive, alpha-beta T cell number ( J:77696 )

• number of CD8+ T cells in spleens of transgenic Mls^a mice is reduced 4-fold compared to uninfected transgenic Mls^b but ~4-fold higher than LCMV-infected Mls^b mice

decreased cytotoxic T cell cytolysis ( J:77696 )

• lysis of LCMV-infected target cells is decreased ~3-fold in uninfected transgenic mice positive for mixed-lymphocyte stimulatory (Mls^a) antigen compared to transgenic mice positive for Mls^b antigen

• LCMV-infected Mls^b show decreased significantly reduced proliferation and specific lysis compared to uninfected transgenic mice

hematopoietic system

decreased T cell proliferation ( J:77696 )

• response of uninfected transgenic Mls^a spleen cells to LCMV is reduced ~3-fold

thymus hypoplasia ( J:77696 )

• numbers of double-positive thymocytes and CD8+ thymocytes are drastically reduced in transgenic mice

decreased double-positive T cell number ( J:77696 )

• numbers of CD4+CD8+ thymocytes are drastically reduced in LCMV-tolerant (carrier) transgenic mice

decreased CD8-positive, alpha-beta T cell number ( J:77696 )

• number of CD8+ T cells in spleens of transgenic Mls^a mice is reduced 4-fold compared to uninfected transgenic Mls^b but ~4-fold higher than LCMV-infected Mls^b mice

decreased cytotoxic T cell cytolysis ( J:77696 )

• lysis of LCMV-infected target cells is decreased ~3-fold in uninfected transgenic mice positive for mixed-lymphocyte stimulatory (Mls^a) antigen compared to transgenic mice positive for Mls^b antigen

• LCMV-infected Mls^b show decreased significantly reduced proliferation and specific lysis compared to uninfected transgenic mice

endocrine/exocrine glands

thymus hypoplasia ( J:77696 )

• numbers of double-positive thymocytes and CD8+ thymocytes are drastically reduced in transgenic mice

cellular

decreased T cell proliferation ( J:77696 )

• response of uninfected transgenic Mls^a spleen cells to LCMV is reduced ~3-fold

Genotype
MGI:3817864

tg21

• Allelic Composition: Tg(TcrLCMV)327Sdz/?
• Genetic Background: involves: C57BL/6 * DBA/2J

immune system

abnormal T cell differentiation ( J:97610 )

• T cells expressing the transgene preferentially develop into CD8⁺ peripheral T cells

• there is only minimal rearrangement of endogenous TCRalpha chains needed in double-positive thymocytes to express a transgenic TCR, so that mice have very few CD4 single-positive thymocytes or CD4⁺ peripheral T cells

decreased CD4-positive, alpha-beta T cell number ( J:97610 )

• very few CD4⁺T cells are found in the thymus or periphery

hematopoietic system

abnormal T cell differentiation ( J:97610 )

• T cells expressing the transgene preferentially develop into CD8⁺ peripheral T cells

• there is only minimal rearrangement of endogenous TCRalpha chains needed in double-positive thymocytes to express a transgenic TCR, so that mice have very few CD4 single-positive thymocytes or CD4⁺ peripheral T cells

decreased CD4-positive, alpha-beta T cell number ( J:97610 )

• very few CD4⁺T cells are found in the thymus or periphery